注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Immatics NV是一家荷兰的临床阶段生物制药公司。该公司专注于T细胞受体的发现和开发业务,旨在实现针对这些目标的强大且特定的T细胞反应。该公司开发靶向免疫疗法,着重于通过两种不同的治疗方式治疗实体瘤:过继细胞疗法(ACT)和抗体样TCR双特异性抗体(TCER)。该公司全资持有8个治疗项目,其中4个正在临床试验中,包括针对实体癌的IMA201(MAGEA4 / 8)、IMA202(MAGEA1)和ACTolog IMA 101(多目标先导试验)及针对血液学和实体瘤的IMA203(PRAME),以及4种尚处于临床前开发阶段针对实体癌的IMA204(COL6A3)和IMA401(睾丸癌抗原),及针对血液学和实体瘤的ACTallo IMA301(癌症睾丸抗原)和IMA402(癌症睾丸抗原)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Harpreet Singh | 48 | 2019 | CEO, MD, Member of Management Board & Executive Director |
Michael G. Atieh | 70 | 2020 | Independent Non-Executive Director |
Paul Rutherford Carter | 62 | 2020 | Independent Non-Executive Director |
Crystal L. Mackall | - | 2020 | Co-Chair of the Scientific Advisory Board |
Patrick Hwu | - | 2021 | Co-Chair of the Scientific Advisory Board |
Heather L. Mason | 61 | 2020 | Independent Vice Chair of the Board of Directors |
Peter Alan Chambré | 67 | 2012 | Non-Executive Chairman |
Roland Kontermann | - | 2020 | Member of Scientific Advisory Board |
Dirk Busch | - | 2021 | Member of Scientific Advisory Board |
Gwendolyn K. Binder | 48 | 2020 | Member of Scientific Advisory Board |
Adam Leo Stone | 43 | 2020 | Independent Non-Executive Director |
Hidde L. Ploegh | - | 2020 | Member of Scientific Advisory Board |
Cassian Yee | - | - | Member of Scientific Advisory Board |
Eliot Richard Forster | 57 | 2020 | Independent Non-Executive Director |
Mathias Hothum | 56 | 2023 | Non-Executive Director |
Anne Kerber | - | 2023 | Member of Scientific Advisory board |
Hans-Georg Rammensee | - | 2000 | Co-Founder & Member of the Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核